Research Paper Volume 15, Issue 1 pp 37—52

Figure 5. Pharmacological modulation of RORα affects CNV lesion size in mice. (A) A cartoon of the drug treatment timeline in laser-induced CNV. RORα inverse agonist (SR3335), agonist (SR1078), or vehicle control was intraperitoneally injected (daily) into C57BL/6J mice after laser-induced CNV. (B) Representative images of isolectin-stained (red) choroidal flat mounts, isolated from mice of all treatment groups on day 7 after laser photocoagulation. Scale bars, 500 μm. (C) Quantification of isolectin-stained CNV area showed significantly increased CNV lesion size in the mice treated with SR3335, and while as the CNV lesion size in the SR1078-treated group did not show significant change, compared to the vehicle control treated group (n = 5–8 mice/group). (D) Vascular leakage from CNV lesions were assessed by fundus fluorescein angiography (FFA) at day 6 after laser photocoagulation and graded on an ordinal scale of the fluorescein leakage appearance: grade 0 (no leakage); grade 1 (questionable leakage); grade 2A (leaky); grade 2B (pathologically significant leakage). n = 5–8 mice/group. Data are presented as mean ± SEM. ^*P ≤ 0.05.